Edition:
United States

Innoviva Inc (INVA.OQ)

INVA.OQ on NASDAQ Stock Exchange Global Select Market

15.74USD
22 Oct 2018
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$15.74
Open
$15.71
Day's High
$15.81
Day's Low
$15.64
Volume
242,668
Avg. Vol
238,503
52-wk High
$17.98
52-wk Low
$11.47

Chart for

About

Innoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium... (more)

Overall

Beta: 2.29
Market Cap(Mil.): $1,559.16
Shares Outstanding(Mil.): 101.51
Dividend: --
Yield (%): --

Financials

  INVA.OQ Industry Sector
P/E (TTM): 10.74 29.75 32.14
EPS (TTM): 1.43 -- --
ROI: 50.15 13.18 12.83
ROE: -- 15.14 14.95

BRIEF-Innoviva Names Geoffrey Hulme As Interim Principal Executive Officer

* INNOVIVA NAMES GEOFFREY HULME AS INTERIM PRINCIPAL EXECUTIVE OFFICER Source text for Eikon: Further company coverage:

May 22 2018

BRIEF-Innoviva Reports Q1 Adjusted Earnings Per Share $0.35

* Q1 EARNINGS PER SHARE VIEW $0.53 -- THOMSON REUTERS I/B/E/S

Apr 26 2018

Earnings vs. Estimates